DexCom Inc - Asset Resilience Ratio
DexCom Inc (DXCM) has an Asset Resilience Ratio of 17.05% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read DexCom Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how DexCom Inc's Asset Resilience Ratio has changed over time. See DexCom Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down DexCom Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DXCM market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.08 Billion | 17.05% |
| Total Liquid Assets | $1.08 Billion | 17.05% |
Asset Resilience Insights
- Good Liquidity Position: DexCom Inc maintains a healthy 17.05% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
DexCom Inc Industry Peers by Asset Resilience Ratio
Compare DexCom Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Sino Medical Sciences Technology In
SHG:688108 |
Medical Devices | 0.66% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 5.46% |
|
Beijing Succeeder Technology Inc
SHG:688338 |
Medical Devices | 28.66% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 8.60% |
|
Respiri Ltd
AU:RSH |
Medical Devices | 0.46% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.39% |
|
Duearity AB
ST:DEAR |
Medical Devices | 145.62% |
Annual Asset Resilience Ratio for DexCom Inc (2005–2025)
The table below shows the annual Asset Resilience Ratio data for DexCom Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 17.05% | $1.08 Billion | $6.34 Billion | -13.38pp |
| 2024-12-31 | 30.43% | $1.97 Billion | $6.48 Billion | -4.01pp |
| 2023-12-31 | 34.44% | $2.16 Billion | $6.26 Billion | +0.80pp |
| 2022-12-31 | 33.64% | $1.81 Billion | $5.39 Billion | -0.38pp |
| 2021-12-31 | 34.03% | $1.68 Billion | $4.93 Billion | -10.03pp |
| 2020-12-31 | 44.05% | $1.89 Billion | $4.29 Billion | -1.34pp |
| 2019-12-31 | 45.39% | $1.09 Billion | $2.40 Billion | +32.42pp |
| 2018-12-31 | 12.97% | $248.60 Million | $1.92 Billion | +1.13pp |
| 2017-12-31 | 11.85% | $107.10 Million | $904.10 Million | +4.60pp |
| 2016-12-31 | 7.25% | $29.20 Million | $402.80 Million | -2.72pp |
| 2015-12-31 | 9.97% | $29.10 Million | $292.00 Million | +3.57pp |
| 2014-12-31 | 6.39% | $11.80 Million | $184.60 Million | -2.91pp |
| 2013-12-31 | 9.31% | $11.40 Million | $122.50 Million | -29.00pp |
| 2012-12-31 | 38.30% | $40.60 Million | $106.00 Million | -27.57pp |
| 2011-12-31 | 65.87% | $79.36 Million | $120.47 Million | +11.15pp |
| 2010-12-31 | 54.72% | $42.22 Million | $77.16 Million | +2.66pp |
| 2009-12-31 | 52.06% | $24.44 Million | $46.95 Million | +19.67pp |
| 2008-12-31 | 32.39% | $14.37 Million | $44.37 Million | -20.95pp |
| 2007-12-31 | 53.34% | $41.21 Million | $77.26 Million | -2.96pp |
| 2006-12-31 | 56.30% | $36.34 Million | $64.55 Million | +32.89pp |
| 2005-12-31 | 23.41% | $13.28 Million | $56.73 Million | -- |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more